{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-033829","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2026-07-20T10:05:18+00:00","discovered_at":"2026-07-20T10:10:00.263592+00:00","generated_at":"2026-07-20T10:10:04.925080+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Immix Biopharma terminates Richard Graydon; management sees no material impact","bullets":["Richard Graydon terminated effective July 17, 2026, for reasons unrelated to his company activities.","Management states Graydon's short tenure means no material effect on the business.","No replacement or further details on Graydon's role were disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-033829","json":"https://secwatch.observer/filing/0001493152-26-033829.json","markdown":"https://secwatch.observer/filing/0001493152-26-033829.md","text":"https://secwatch.observer/filing/0001493152-26-033829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226033829/0001493152-26-033829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226033829/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T10:10:04.925080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}